HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1
Till Schoofs, Florian Klein, Malte Braunschweig, Edward F Kreider, Anna Feldmann, Lilian Nogueira, Thiago Oliveira, Julio C C Lorenzi, Erica H Parrish, Gerald H Learn, Anthony P West Jr, Pamela J Bjorkman, Sarah J Schlesinger, Michael S Seaman, Julie Czartoski, M Juliana McElrath, Nico Pfeifer, Beatrice H Hahn, Marina Caskey, Michel C Nussenzweig, Till Schoofs, Florian Klein, Malte Braunschweig, Edward F Kreider, Anna Feldmann, Lilian Nogueira, Thiago Oliveira, Julio C C Lorenzi, Erica H Parrish, Gerald H Learn, Anthony P West Jr, Pamela J Bjorkman, Sarah J Schlesinger, Michael S Seaman, Julie Czartoski, M Juliana McElrath, Nico Pfeifer, Beatrice H Hahn, Marina Caskey, Michel C Nussenzweig
Abstract
3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding site on the viral envelope spike. When administered passively, this antibody can prevent infection in animal models and suppress viremia in HIV-1-infected individuals. Here we report that HIV-1 immunotherapy with a single injection of 3BNC117 affects host antibody responses in viremic individuals. In comparison to untreated controls that showed little change in their neutralizing activity over a 6-month period, 3BNC117 infusion significantly improved neutralizing responses to heterologous tier 2 viruses in nearly all study participants. We conclude that 3BNC117-mediated immunotherapy enhances host humoral immunity to HIV-1.
Trial registration: ClinicalTrials.gov NCT02018510.
Copyright © 2016, American Association for the Advancement of Science.
Figures
Source: PubMed